Skip to main content
Top
Published in: Medical Oncology 1/2015

01-01-2015 | Letter to the Editor

Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia

Authors: Li-juan Zhang, Yi-min Gan, Liang Yu

Published in: Medical Oncology | Issue 1/2015

Login to get access

Excerpt

Acute promyelocytic leukemia (APL) is a common malignant hematological tumor characterized by the t(15;17) chromosome translocation, which results in the fusion of the retinoic acid receptor alpha (RARα) gene on chromosome 17 and the PML gene on chromosome 15, with the expression of a PML–RARα fusion protein [1]. The BCR/ABL fusion gene, which is caused by the t(9;22) chromosome translocation, is mainly found in patients with chronic myeloid leukemia (CML). However, it is also the most common cytogenetic abnormality detected in adult acute lymphoblastic leukemia (about 30 %) and is also observed in a few acute myeloid leukemia (AML) patients. However, BCR/ABL is rarely found in APL. Here, we report the occurrence of both PML–RARα and BCR/ABL in a patient with primary APL. …
Literature
1.
go back to reference de The H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor a gene to a novel transcriptional focus. Nature. 1990;347(6293):558–61.PubMedCrossRef de The H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor a gene to a novel transcriptional focus. Nature. 1990;347(6293):558–61.PubMedCrossRef
2.
go back to reference De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801–6.PubMed De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801–6.PubMed
3.
go back to reference Kaito K, Otsubo H, Dobashi N, et al. CD2 + tetraploid acute promyelocytic leukemia variant with double (15;17) translocations. Int J Hematol. 2005;81(1):29–31.PubMedCrossRef Kaito K, Otsubo H, Dobashi N, et al. CD2 + tetraploid acute promyelocytic leukemia variant with double (15;17) translocations. Int J Hematol. 2005;81(1):29–31.PubMedCrossRef
4.
go back to reference Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–65.PubMedCrossRef Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–65.PubMedCrossRef
5.
go back to reference Hall MJ, Li L, Wiernik PH, et al. BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006;47(4):765–7.PubMed Hall MJ, Li L, Wiernik PH, et al. BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006;47(4):765–7.PubMed
6.
go back to reference Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res. 2004;28(6):579–86.PubMedCrossRef Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res. 2004;28(6):579–86.PubMedCrossRef
7.
go back to reference Mao L, Wang H, Cheng Y, et al. Occurrence of t(15;17)(q22;q21) and t(9;22)(q34;q11) in a patient with acute promyelocytic leukemia. Leuk Lymphoma. 2009;50(3):466–70.PubMedCrossRef Mao L, Wang H, Cheng Y, et al. Occurrence of t(15;17)(q22;q21) and t(9;22)(q34;q11) in a patient with acute promyelocytic leukemia. Leuk Lymphoma. 2009;50(3):466–70.PubMedCrossRef
8.
go back to reference Sun X, He Y, Mao C, et al. BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results. Leuk Lymphoma. 2014;55(2):435–8.PubMedCrossRef Sun X, He Y, Mao C, et al. BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results. Leuk Lymphoma. 2014;55(2):435–8.PubMedCrossRef
9.
go back to reference Hematology Branch of the Chinese Medical Association of acute promyelocytic leukemia China Medical Guide. Chinese Journal of Hematology. 2011; 32(12):885–886. Hematology Branch of the Chinese Medical Association of acute promyelocytic leukemia China Medical Guide. Chinese Journal of Hematology. 2011; 32(12):885–886.
10.
go back to reference Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of Chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935–42.PubMed Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of Chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935–42.PubMed
11.
go back to reference Perkins C, Kim CN, Fang G, et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells. Blood. 2000;95(3):1014–22.PubMed Perkins C, Kim CN, Fang G, et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells. Blood. 2000;95(3):1014–22.PubMed
12.
go back to reference Porosnicu M, Nimmanapalli R, Nguyen D, et al. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia. 2001;15(5):772–8.PubMedCrossRef Porosnicu M, Nimmanapalli R, Nguyen D, et al. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia. 2001;15(5):772–8.PubMedCrossRef
13.
go back to reference Rosde PL, Johnson K, O’Dwyer ME, et al. In vitro studies of the combination of imatinib mesylate(Gleevec) and arsenic trioxide(Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002;30(7):729–37.CrossRef Rosde PL, Johnson K, O’Dwyer ME, et al. In vitro studies of the combination of imatinib mesylate(Gleevec) and arsenic trioxide(Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002;30(7):729–37.CrossRef
14.
go back to reference Du Y, Wang K, Fang H, et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood. 2006;107(4):1582–90.PubMedCrossRef Du Y, Wang K, Fang H, et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood. 2006;107(4):1582–90.PubMedCrossRef
15.
go back to reference Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127(4):642–50.PubMedCrossRef Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127(4):642–50.PubMedCrossRef
Metadata
Title
Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia
Authors
Li-juan Zhang
Yi-min Gan
Liang Yu
Publication date
01-01-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0382-0

Other articles of this Issue 1/2015

Medical Oncology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.